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Abstract
Oseltamivir (TamifluH) is the most important antiviral drug available and a cornerstone in the defence against a future
influenza pandemic. Recent publications have shown that the active metabolite, oseltamivir carboxylate (OC), is not
degraded in sewage treatment plants and is also persistent in aquatic environments. This implies that OC will be present in
aquatic environments in areas where oseltamivir is prescribed to patients for therapeutic use. The country where oseltamivir
is used most is Japan, where it is used to treat seasonal flu. We measured the levels of OC in water samples from the Yodo
River system in the Kyoto and Osaka prefectures, Japan, taken before and during the flu-season 2007/8. No OC was detected
before the flu-season but 2–58 ng L
21 was detected in the samples taken during the flu season. This study shows, for the
first time, that low levels of oseltamivir can be found in the aquatic environment. Therefore the natural reservoir of influenza
virus, dabbling ducks, is exposed to oseltamivir, which could promote the evolution of viral resistance.
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Introduction
Oseltamivir (TamifluH) is the most important of the few antiviral
drugs available for treatment of seasonal flu and a cornerstone in
the defense against a future influenza pandemic. Most govern-
ments have built their preparedness plans around stockpiling
oseltamivir and it is recommended by WHO both as treatment
and prophylaxis in a pandemic situation [1].
Influenza A virus is a zoonosis, with its natural reservoir in
dabbling ducks [2]. It belongs to the orthomyxoviridae, a negative
strand RNA virus family, which also includes influenza B and C;
however the two latter are of less importance as human pathogens.
The different influenza A virus subtypes are named after the type
of two cell-surface glycoproteins, hemagglutinin (HA) and
neuraminidase (NA) [3]. At present, there are two subtypes,
H1N1 and H3N2, which cause the annual seasonal influenza
epidemics [3]. All influenza infections render humoral immuno-
logic memory, but antigenic changes are so frequent that previous
infections often give only limited immunity to concurrent virus.
This may be a viral strategy, where the low specificity of the virus
polymerase generates frequent mismatches and a high rate of
mutations. The influenza virus has another, more drastic way of
genetic change, where genetic elements from two viruses infecting
the same cell can be recombined. This process, termed ‘genetic
reassortment’, promotes rapid evolutionary changes and is the key
to the genesis of new strains of human influenza capable of causing
a pandemic [3–5]. Both the ‘Asian flu’ in 1957 (H2N2) and the
‘Hong Kong flu’ in 1968 (H3N2) were reassortments between
human-adapted seasonal influenza strains and contemporary
avian strains [6].
Oseltamivir is a neuraminidase inhibitor administered orally as a
prodrug, oseltamivir phosphate, which is converted to the active
metabolite OC in the liver and then excreted without further
metabolism through the urine [7]. In a previous study, we have
shown that the active metabolite of oseltamivir, oseltamivir
carboxylate (OC) is neither degraded nor removed in sewage
treatment plants (STPs) [8]. Thus, we assumed that OC can be
present in the aquatic environment. Recent publications show that
OC is quite persistent in aquatic environments and is only removed
by microbial degradation associated with sediment [9,10]. A
hypothesis hasbeen presented that OC residuesinthe environment,
either after usage during a pandemic or for treatment of seasonal
influenza, could expose the natural reservoir of influenza virus,
dabbling ducks, to low levels of this antiviral which could promote
resistance development [8,11]. OC usage during a pandemic could
also have other ecotoxicological effects [12].
Japan is the top per-capita-consumer of oseltamivir; the
manufacturer Roche estimates that 6 of 16 million infected
Japanese were prescribed the drug during the 2004/05 flu season
[13]. A study was conducted with the assumption that a) OC is
detectable in Japanese waterways, b) levels increase at the peak of
the flu season and c) levels are higher closer to the outlet of a STP.
We chose to study the Yodo River system in the Kyoto and Osaka
prefectures, a densely populated area located off-sea.
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Sampling
Surface water was collected before (June 2007) and during
(December 2007 and February 2008) the flu season 2007/8 from
totally six sites (R1–R6) in three rivers of the Yodo River system
(Fig. 1). R1 (N17u 32.396 E78u 14.590, Kyoto), R2 (N17u 34.422
E78u 21.359, Kyoto), R3 (N17u 34.422 E78u 21.359, Kyoto), R4
(N17u 34.451 E78u 21.390, Kyoto), R5 (N17u 33.165 E78u 19.990,
Osaka) and R6 (N17u 36.845 E78u 11.598, Osaka). Repeated
sampling was performed at sites R1, R2 and R4. R1 was located in
a rural area of Kamo River, before the river enters more
populated areas. In Katsura River samples were taken 1 km
upstream (R2) and 2.5 km downstream (R4) of the outlet of one of
the major STPs in Kyoto prefecture. In February 2008, additional
sampling was performed closer to the STP (R3), 0.5 km
downstream of its outlet, and in the Yodo River (R5 and R6) in
the Osaka prefecture, respectively, where the water has run
through almost all of the river system, collecting the sewage outlets
from approximately 5 million inhabitants. Duplicate 500 ml
samples were taken at each location; these were immediately
frozen and kept at 218uC until analysis.
Chemicals
Oseltamivir carboxylate (OC), (RO0640802-002; lot:
01007B243804) and Oseltamivir carboxylate labelled with deute-
rium (OCD3), (RO0604802-004; lot: 511-001-2197/4) were
obtained from Roche (F. Hoffmann-La Roche Ltd, Basel,
Switzerland). Formic acid, ammonium hydroxide 25% and
methanol (HPLC-grade) were purchased from JT Baker (Deven-
ter, the Netherlands), acetonitrile (HPLC-grade) from Fischer
Chemicals (Zurich, Switzerland) and sulphuric acid from Merck
(Darmstadt, Germany). The purified water (resistivity, 18.2 MV
cm) was prepared by an ELGA MAXIMA HPLC ultra pure water
system (ELGA, High Wycombe Bucks, UK). Standard stock
solutions of OC and OCD3, 100 ng mL
21, were prepared in water
(10 mL) and kept dark at 4uC.
Figure 1. Sampling locations in Kyoto (R1–R4) and Osaka (R5–R6) prefectures, Japan.
doi:10.1371/journal.pone.0006064.g001
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Samples were filtered through 0.45 mmM F
TM-membrane filters
(Millipore, Sundbyberg, Sweden) before acidification to pH 3
using sulphuric acid. The internal standard OCD3 was added to
each sample to an amount of 500 ng. The Strata-X-C (200 mg,
6 mL) mixed mode cation exchange sorbent (Phenomenex, email:
international@phenomenex.com) used for the solid phase extrac-
tion (SPE) was conditioned and equilibrated by 2.0 ml of methanol
and 2.0 ml of deionized water. 500 mL of the samples were
applied to the SPE columns at a flow rate of 5 mL min
21.
Impurities were removed by 2.0 ml 0.1% sulphuric acid and the
sorbents were dried (1 min at 10’’ Hg). Neutral and acidic
components were removed by 2 mL of methanol and wasted,
followed by elution of the analytes by 2 mL of 5% NH4OH in
methanol. The eluates were evaporated to approximately 20 ml
using air and then reconstituted in acetonitrile in water (1:1),
containing 0.1% formic acid, to a final extract volume of 1.0 ml.
Liquid Chromatography-Mass Spectrometry
Sample extracts and calibration solutions (7.5 ml) were injected
into a Waters Acquity
TM Ultra Performance LC system connected
to a Micromass Quattro Ultima triple quadruple mass spectrom-
eter. OC and the internal standard, OCD3, were separated by
using: equal amounts of the mobile phases H20 and ACN, both
containing 0.1% (v/v) formic acid; a flow rate of 0.200 ml min
21
and a Waters Acquity
TM UPLC BEH C18 (2.1650 mm, 1.7 mm
particle size) analytical column. The electrospray was held in
positive ion mode and the capillary and cone voltage were kept at
3.9 kV and 45 V, respectively. The source temperature was 110uC
and the desolvation temperature was 310uC. The following
transitions were monitored 284.9.196.6 (OC) and 287.9.199.9
(OCD3). Quantification was based on internal standard calibration
and the peak area ratios of OCD3 and OC [8]. The linearity of the
seven point calibration curve was acceptable (R
2 above 0.997).
LOQ was 1 ng L
21, determined by using the second point in the
calibration curve.
Results
No OC was detected in the surface water collected in June
2007, during the influenza ‘‘off-season’’ (Table 1) and no influenza
patients were reported this week [14]. In December, at the onset of
the flu season (Fig. 2), 2 and 7 ng L
21 of OC was detected
upstream (R2) and downstream (R4), respectively, of the STP
(Table 1). At the peak of the flu-season, the levels of OC
downstream the STP (R4) increased to 11 and 10 ng L
21, and OC
levels of 19 ng L
21 was measured at the additional sampling point
(R3) closer to the STP, while the levels of OC detected up-stream
of the STP and in Kamo River were similar to those found in
December (Table 1). At the peak of the flu-season, the OC
concentrations in the Yodo River were also measured and the
detected levels were 12 ng L
21 (R5) and 58 ng L
21 (R6) (Table 1).
In Kyoto City, 6748 individuals were reported to have been
affected by the flu during week 7 (11–17th of February) [14]
(Fig. 2), i.e. the week we sampled water at site R2–R6. Assuming
that approximately 40% received oseltamivir treatment [13], this
corresponds to a weekly usage of 1.3 kg OC or 0.18 kg day
21
(estimated from 30% pediatric dosage, 70% adult dosage and 75%
pro-drug conversion to OC, respectively). Calculations from the
daily use and the average flow in Katsura River during the 12th of
February (2291000 m
3 day
21) yield a predicted environmental
concentration (PEC) of 78 ng L
21. This PEC value is similar to the
OC levels that we measured in Katsura River downstream of the
STP on the same day. Furthermore, some of the levels detected in
this study are close the IC50 (concentration that causes 50%
inhibition) of OC, which however depends heavily on type of virus
Figure 2. Number of individuals in Kyoto city and Kyoto prefecture affected by the flu during the flu season 07/08 [14]. Arrows
indicate sampling events.
doi:10.1371/journal.pone.0006064.g002
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21 have
been reported [15,16].
Discussion
We found that the active metabolite of oseltamivir is present in
Japanese waterways at clearly detectable levels. The levels increase
at the peak of the flu season and are in the same magnitude as the
PEC value estimated from the total use of oseltamivir, and close to
the IC50 of OC. Our results suggest that OC levels are higher
closer to major STPs and further downstream in a river system.
Subsequently, the natural reservoir of influenza virus, dabbling
ducks [2], living in the aquatic environments in Japan or another
area where oseltamivir is used widely, are exposed to OC. As
influenza in dabbling ducks is a gastrointestinal infection, their
bowel can contain replicating virus as well as oseltamivir, which
could promote the evolution of viral resistance.
Strain-specific vaccines will not be available at the start of a
pandemic. The only intervention possible in the absence of
vaccines would be the use of antivirals. Earlier pandemic influenza
viruses have contained genetic material from avian strains and if
oseltamivir-resistance is induced and transferred from the avian
reservoir to a virus with pandemic potential there is an imminent
risk that one of the cornerstones in pandemic preparedness have
been disarmed. It is therefore essential to investigate the biological
significance of the observed levels of OC in the environment.
Acknowledgments
We thank F.Hoffmann-La Roche Ltd. for donating oseltamivir carboxylate
and oseltamivir carboxylate labelled with deuterium. We thank The
Swedish Research Council for Environment, Agricultural Sciences and
Spatial Planning and the Swedish Research Council for financial support.
Author Contributions
Conceived and designed the experiments: BO JF. Performed the
experiments: HS RHL JF. Analyzed the data: HS JJ BO RHL JF.
Contributed reagents/materials/analysis tools: HT. Wrote the paper: HS
JJ BO HT JF. Conducted the sampling: HS JJ.
References
1. WHO (2005) Influenza antiviral medicinal products for potential use during a
pandemic. WHO Drug Information 19: 273–285.
2. Olsen B, Munster VJ, Wallensten A, Waldenstrom J, Osterhaus ADME, et al.
(2006) Global Patterns of Influenza A Virus in Wild Birds. Science 312:
384–388.
3. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y (1992)
Evolution and Ecology of Influenza-A Viruses. Microbiol Rev 56: 152–179.
4. Chen L-M, Davis CT, Zhou H, Cox NJ, Donis RO (2008) Genetic
Compatibility and Virulence of Reassortants Derived from Contemporary
Avian H5N1 and Human H3N2 Influenza A Viruses. PLoS Pathog 4(5):
e1000072.
5. Lipatov AS, Govorkova EA, Webby RJ, Ozaki H, Peiris M, et al. (2004)
Influenza: Emergence and Control. J Virol 78: 8951–8959.
6. Kawaoka Y, Krauss S, Webster RG (1989) Avian-to-human transmission of the
PB1 gene of influenza A viruses in the 1957 and 1968 pandemics. J Virol 63:
4603–4608.
7. Sweetman SC, ed (2007) Martindale: The Complete Drug Reference. London:
Pharmaceutical Press, Electronic version, (Edition 070214).
8. Fick J, Lindberg RH, Tysklind M, Haemig PD, Waldenstro ¨m J, et al. (2007)
Antiviral Oseltamivir Is not Removed or Degraded in Normal Sewage Water
Treatment: Implications for Development of Resistance by Influenza A Virus.
PLoS ONE 2(10): e986.
9. Accinelli C, Caracciolo AB, Grenni P (2007) Degradation of the antiviral drug
oseltamivir carboxylate in surface water samples. Intern J Environ Anal Chem
8(87): 570–587.
10. Sacca ` ML, Accinelli C, Fick J, Lindberg R, Olsen B (2009) Environmental fate
of the antiviral drug Tamiflu in two aquatic ecosystems. Chemosphere 75:
28–33.
11. Singer AC, Miles AN, Gould EA, Johnson AC (2007) Potential Risks Associated
with the Proposed Widespread Use of Tamiflu. Env Health Persp 115: 102–106.
12. Singer AC, Howard BM, Johnson AC, Knowles CJ, Jackman S, et al. (2008)
Meeting Report: Risk Assessment of Tamiflu Use Under Pandemic Conditions.
Env Health Persp 116: 1563–7.
13. F.Hoffmann-La Roche Ltd (2005) (accesessed February 14, 2007, at http://
www.roche.com/med-cor-2005-10-18).
14. Kyoto Prefecture Infectious Disease Surveillance Center (2008) (accesessed May
28, 2008, at http://www.kentai-pref-kyoto.jp).
15. Monto AS, McKimm-Breschkin J, Macken C, Hampson AW, Hay A, et al.
(2006) Detection of Influenza Viruses Resistant to Neuraminidase Inhibitors in
Global Surveillance during the First 3 years of Their Use Antimicrob. Agents
Chemother 50: 2395–2402.
16. Gubareva LV, Webster RG, Hayden FG (2001) Comparison of the Activities of
Zanamivir, Oseltamivir, and RWJ-270201 against Clinical Isolates of Influenza
Virus and Neuraminidase Inhibitor-Resistant Variants. Antimicrob Agents
Chemother 45: 3403–8.
Table 1. Average water concentrations (ng L
21)o f
oseltamivir carboxylate (OC) measured in Kyoto (R1–R4) and
Osaka (R5–R6) prefectures, Japan.
Date Week
Kamo
River Katsura River Yodo River
R1 R2 R3 R4 R5 R6
2007-06-13 nd nd - nd - -
2007-12-17 50 - 2 - 7 - -
2008-02-04 5 2 4 - 11 - -
2008-02-12 6 - 4 19 10
2008-02-15 6 - - - - 12 58
doi:10.1371/journal.pone.0006064.t001
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